Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 3/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | CD44 | P16070 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8084188 | 0.89 | TSHR (0.57) | TSHRHTR2CNOS3NOS2MAOB | |
| SCHEMBL23867 | 0.86 | TSHR (0.46) | TSHRHTR2CNOS3NOS2MAOB | |
| SCHEMBL4465325 | 0.75 | TSHR (0.71) | TSHRHTR2CNOS3NOS2MAOB | |
| SCHEMBL34906 | 0.75 | — | — | |
| SCHEMBL33555 | 0.75 | — | — | |
| SCHEMBL29351986 | 0.75 | — | — | |
| SCHEMBL11223077 | 0.75 | NOS3 (0.50) | TSHRNOS3NOS2MAOBCYP2A6 | |
| SCHEMBL5424510 | 0.73 | TSHR (0.43) | TSHRHTR2CNOS3NOS2MAOB | |
| Bromide SCHEMBL917076 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL21176564 | 0.72 | TSHR (0.67) | TSHRHTR2CNOS3NOS2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 357 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-11-05 | — | — | US | claimed |
| US-8420630-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-04-16 | — | — | US | claimed |
| EP-2090571-B1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-16 | — | — | EP | claimed |
| EP-2448926-A1 | FLAVIN DERIVATIVES | Biorelix, Inc. (US) | 2012-05-09 | — | — | EP | claimed |
| WO-2011008247-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-01-20 | — | — | WO | claimed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | claimed |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | claimed |
| US-7709480-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-04 | — | — | US | claimed |
| EP-1438053-B1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-09-10 | — | — | EP | claimed |
| EP-1886994-A1 | Cyclic amine compounds as CCR5 antagonists | Takeda Pharmaceutical Company Limited (JP) | 2008-02-13 | — | — | EP | claimed |
| US-5663183-A | CEREBRAL DISORDERS | SYNTHELABO (FR) | 1997-09-02 | — | — | US | claimed |
| US-5447928-A | Antiischemic agents and nervous system disorders | SYNTHELABO (FR) | 1995-09-05 | — | — | US | claimed |
| US-4820695-A | GRAMNEGATIVE BACTERIA | ELI LILLY AND COMPANY (US) | 1989-04-11 | — | — | US | claimed |
| EP-0124216-B1 | C-20- AND C-23-MODIFIED MACROLIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1988-10-26 | — | — | EP | claimed |
| EP-0103465-B1 | 20-AMINO MACROLIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1986-09-10 | — | — | EP | claimed |
| EP-0124216-A1 | C-20- and C-23-modified macrolide derivatives | ELI LILLY AND COMPANY (US) | 1984-11-07 | — | — | EP | claimed |
| US-4468511-A | C-20- And C-23-Modified macrolide derivatives | ELI LILLY AND COMPANY (US) | 1984-08-28 | — | — | US | claimed |
| EP-0103465-A1 | 20-Amino macrolide derivatives | ELI LILLY AND COMPANY (US) | 1984-03-21 | — | — | EP | claimed |
| EP-0023569-B1 | DERIVATIVES OF CARBOXYLIC ACIDS, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1983-06-22 | — | — | EP | claimed |
| EP-0023569-A1 | Derivatives of carboxylic acids, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1981-02-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | CNR2, CNR1, SLC18A2 | TSHR 1696/4885HTR2C 21/4885NOS3 3559/4885 |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | TSHR 1436/4885HTR2C 1877/4885NOS3 2622/4885 |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | KDM1B, KDM1A, KDM2A | TSHR 4487/4885HTR2C 3558/4885NOS3 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.